Pharmaceutical company Mylan NV announced that certain employees of Mylan in Italy were served with search warrants issued by the public prosecutor’s office in Milan, Italy, seeking information concerning interactions with an Italian hospital and sales of certain reimbursable drugs.
The company was not immediately available for additional details outside business hours.
Shares of the drugmaker were down 1.2% at US$37.44 after the bell.
In 2016, Mylan’s pricing of the EpiPen, an epinephrine autoinjector, became controversial. An investigation was opened into whether Mylan had misclassified the EpiPen under the Medicaid Drug Rebate Program.
In October 2016, Mylan settled these investigations with the US Department of Justice, agreeing to pay US$465 million.
Full Content: Fierce Pharma
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google ExecAdmitted Firm’s Goal Was to “Crush” Digital Ad Rivals, According to Court Docs
Sep 11, 2024 by
CPI
Former Michigan Football Stars File $50 Million Antitrust Lawsuit Against NCAA
Sep 11, 2024 by
CPI
Oasis Fans Could Be in Line for Ticket Refunds Amid Antitrust Concerns
Sep 11, 2024 by
CPI
FCC Chair Calls for More Competition to SpaceX’s Starlink Network
Sep 11, 2024 by
CPI
Singapore Salon Director Jailed for Contempt in Consumer Protection Case
Sep 11, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Canada & Mexico
Sep 3, 2024 by
CPI
Competitive Convergence: Mexico’s 30-Year Quest for Antitrust Parity with its Northern Neighbor
Sep 3, 2024 by
CPI
Competition and Digital Markets in North America: A Comparative Study of Antitrust Investigations in Mexico and the United States
Sep 3, 2024 by
CPI
Recent Antitrust Development in Mexico: COFECE’s Preliminary Report on Amazon and Mercado Libre
Sep 3, 2024 by
CPI
The Cost of Making COFECE Disappear
Sep 3, 2024 by
CPI